Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates

被引:62
作者
Gangjee, A [1 ]
Zeng, YB
McGuire, JJ
Mehraein, F
Kisliuk, RL
机构
[1] Duquesne Univ, Grad Sch Pharmaceut Sci, Div Med Chem, Pittsburgh, PA 15282 USA
[2] Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA
[3] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA
关键词
D O I
10.1021/jm040123k
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
Bridge homologation of the previously reported classical two-carbon-bridged antifolates, a 5-substituted 2,4-diaminofuro[2,3-d]pyrimidine (1) [which is a 6-regioisomer of LY231514 (Alimta)] and a 6-subsituted 2-amino-4-oxopyrrolo[2,3-d]pyrimidine, afforded the three-carbon-bridged antifolates analogues 4 and 5, with enhanced inhibitory activity against tumor cells in culture (EC50 values in the 10(-8)-10(-7) M range or less). These two analogues were synthesized via a 10-step synthetic sequence starting from methyl 4-bromobenzoate (14), which was elaborated to the a-chloromethyl ketone (8) followed by condensation with 2,6-diaminopyrimidin-4-one (7) to afford the substituted furo[2,3-d]pyrimidine 9 and the pyrrolo[2,3-d]pyrimidine 10. Subsequent coupling of each regioisomer with diethyl-L-glutamate followed by saponification afforded 4 and 5. The biological results indicate that elongation of the C8-C9 bridge of the classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidine and 6-substituted 2-amino-4-oxopyrrolo[2,3-d]pyrimidine are highly conducive to antitumor activity in vitro, despite a lack of increase in inhibitory activity against the target enzymes. This supports our original hypothesis that truncation of the B-ring of a highly potent 6-6 ring system to a 6-5 ring system can be compensated by bridge homologation to restore the overall length of the molecule.
引用
收藏
页码:6893 / 6901
页数:9
相关论文
共 32 条
[1]
The crystal structure of thymidylate synthase from Pneumocystis carinii reveals a fungal insert important for drug design [J].
Anderson, AC ;
Perry, KM ;
Freymann, DM ;
Stroud, RM .
JOURNAL OF MOLECULAR BIOLOGY, 2000, 297 (03) :645-657
[2]
THE RENEWED POTENTIAL FOR FOLATE ANTAGONISTS IN CONTEMPORARY CANCER-CHEMOTHERAPY [J].
BERMAN, EM ;
WERBEL, LM .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (02) :479-485
[3]
Blakley R. L., 1969, BIOCH FOLIC ACID REL, P569
[4]
CODY V, 1993, ADV EXP MED BIOL, V338, P481
[5]
DAVISSON VJ, 1989, J BIOL CHEM, V264, P9145
[6]
SYNTHESIS AND ANTIFOLATE ACTIVITY OF 10-DEAZAMINOPTERIN [J].
DEGRAW, JI ;
KISLIUK, RL ;
GAUMONT, Y ;
BAUGH, CM ;
NAIR, MG .
JOURNAL OF MEDICINAL CHEMISTRY, 1974, 17 (05) :552-553
[7]
FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO
[8]
2-J
[9]
Gangjee A, 1996, CURR PHARM DESIGN, V2, P263
[10]
Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent [J].
Gangjee, A ;
Yu, JM ;
McGuire, JJ ;
Cody, V ;
Galitsky, N ;
Kisliuk, RL ;
Queener, SF .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (21) :3837-3851